1887

Abstract

The widespread of hepatitis B virus is a severe global public problem, and the infant hepatitis B vaccine has been proved effective. But the failure of the immune response was reported in studies, and boosters were recommended. There were few studies about the effect of hepatitis B vaccine boosters in different levels of the epidemic area.

Booster immunization is recommended because there may be a lack of immunization in infants vaccinated with the hepatitis B vaccine. In order to verify the effectiveness of booster immunization, this study hypothesized that it worked well in different levels of endemic areas.

To evaluate the effects of hepatitis B vaccine boosters on children from the areas with different prevalence of hepatitis B whose hepatitis B surface antibody (anti-HBs) were negative (<10 mIU ml).

A total of 940 children were initially enrolled in screening; however, 421 were excluded. The participants were divided into three groups according to the different areas they come from: group I, low epidemic area; group II, middle epidemic area; and group III, high epidemic area. In total, 519 subjects were administered three doses of booster hepatitis B vaccine (0–1–6 months, 10 µg). The antibody titre changes were examined at four time points: 1 month after dose 1, 1 month, 1 year and 5 years after dose 3.

The protective seroconversion rates in three groups were 96.30, 97.16, 96.63% at 1 month after dose 1, and 100.00, 100.00, 100.00% at 1 month after dose 3, and 97.79, 100.00, 98.50% at 1 year after dose 3, and 90.77, 93.67, 93.59% at 5 years after dose 3 (>0.05).

This study demonstrates that three doses of booster vaccination have a longtime effect, no matter whether it is in low, middle or high prevalence areas in which subjects live.

Funding
This study was supported by the:
  • JunYao , National Major Science and Technology Projects of China , (Award 2014ZX10004-008)
  • JunYao , National Major Science and Technology Projects of China , (Award No. 2013ZX10004-904)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001274
2020-12-10
2021-03-02
Loading full text...

Full text loading...

References

  1. European Association for the Study of the Liver Clinical practice guidelines on the management of hepatitis B virus infection European association for the study of the liver. J Hepatol 2017; 67:370–398
    [Google Scholar]
  2. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011; 55:183–191 [CrossRef][PubMed]
    [Google Scholar]
  3. Organization WH 2019; Global immunization coverage 2018. http://www.who.int/zh/news-room/fact-sheets/detail/immunization-coverage
  4. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379–1384 [CrossRef][PubMed]
    [Google Scholar]
  5. Van Der Meeren O, Behre U, Crasta P. Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine. Vaccine 2016; 34:2745–2749 [CrossRef][PubMed]
    [Google Scholar]
  6. Beran J, Van Der Meeren O, Leyssen M, D'silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine 2016; 34:2686–2691 [CrossRef][PubMed]
    [Google Scholar]
  7. Chaves SS, Fischer G, Groeger J, Patel PR, Thompson ND et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30:1644–1649 [CrossRef][PubMed]
    [Google Scholar]
  8. Ni Y-H, Chang M-H, Wu J-F, Hsu H-Y, Chen H-L et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730–735 [CrossRef][PubMed]
    [Google Scholar]
  9. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54:801–807 [CrossRef][PubMed]
    [Google Scholar]
  10. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016; 214:16–22 p. [CrossRef][PubMed]
    [Google Scholar]
  11. Su F-H, Cheng S-H, Li C-Y, Chen J-D, Hsiao C-Y et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25:8085–8090 [CrossRef][PubMed]
    [Google Scholar]
  12. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006; 78:169–177 [CrossRef][PubMed]
    [Google Scholar]
  13. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369–375 [CrossRef][PubMed]
    [Google Scholar]
  14. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333–341 [CrossRef][PubMed]
    [Google Scholar]
  15. Lu C-Y, Ni Y-H, Chiang B-L, Chen P-J, Chang M-H et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419–1426 [CrossRef][PubMed]
    [Google Scholar]
  16. Chinchai T, Chirathaworn C, Praianantathavorn K, Theamboonlers A, Hutagalung Y et al. Long-Term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22:125–130 [CrossRef][PubMed]
    [Google Scholar]
  17. Jan C-F, Huang K-C, Chien Y-C, Greydanus DE, Davies HD et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51:1547–1554 [CrossRef][PubMed]
    [Google Scholar]
  18. Zhu C-L, Liu P, Chen T, Ni Z, Lu L-L et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011; 29:7835–7841 [CrossRef][PubMed]
    [Google Scholar]
  19. Wu T-W, Lin HH, Wang L-Y. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 2013; 57:37–45 [CrossRef][PubMed]
    [Google Scholar]
  20. Lu C-Y, Chiang B-L, Chi W-K, Chang M-H, Ni Y-H et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415–1420 [CrossRef][PubMed]
    [Google Scholar]
  21. Wang Y, Chen T, Lu L-L, Wang M, Wang D et al. Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults. Vaccine 2017; 35:1064–1070 [CrossRef][PubMed]
    [Google Scholar]
  22. Lu S, Ren J, Li Q, Jiang Z, Chen Y et al. Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization. Hum Vaccin Immunother 2017; 13:903–908 [CrossRef][PubMed]
    [Google Scholar]
  23. But DY-K, Lai C-L, Lim W-L, Fung J, Wong DK-H et al. Twenty-Two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26:6587–6591 [CrossRef][PubMed]
    [Google Scholar]
  24. Yao J, Shan H, Chen Y, Jiang ZG, Dai XW et al. The one year effects of three doses of hepatitis B vaccine as a booster in anti-HBs-negative children 11-15 years after primary immunization; China, 2009-2011. Hum Vaccin Immunother 2015; 11:00–1119 [CrossRef][PubMed]
    [Google Scholar]
  25. Alanko Blomé M, Björkman P, Flamholc L, Jacobsson H, Widell A. Vaccination against hepatitis B virus among people who inject drugs - A 20year experience from a Swedish needle exchange program. Vaccine 2017; 35:84–90 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001274
Loading
/content/journal/jmm/10.1099/jmm.0.001274
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error